Pharmaceutical News

RSS

Bextra qui tam lawsuit leads to Pfizer's whopping $2.3 billion settlement

The decision by a Pfizer sales representative in Florida to file a whistleblower ("qui tam") lawsuit in 2003 kicked off the federal and state investigations that led to Pfizer's record-breaking $2.3 billion settlement today.

3 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Hong Kong's healthcare workers to refuse H1N1 vaccine, says study

According to a study released August 26, 2009 by the British Medical Journal, more than half of Hong Kong's healthcare workers surveyed said they would refuse the H1N1 shot, which is not yet available, because they are afraid of side effects and doubt how safe and effective it will be. More importantly, the study suggested the trend would be repeated worldwide.

3 Sep 2009

BioMS Medical update on dirucotide development

BioMS Medical Corp. (TSX: MS), today provided an update on developments in respect of dirucotide, its drug candidate for multiple sclerosis (MS).

2 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.

2 Sep 2009

Cavit Sciences and McCoy form an agreement to finalize their merger

Cavit management has been negotiating with Randall McCoy and Joe Connell principle owners of McCoy Enterprises LLC to merge our companies. Maggie Smyth, CEO of Cavit states, “We all feel very good about this fit so we have added a breakup clause to show our commitment to each other”.

2 Sep 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009).

2 Sep 2009

Ferguson OTC Center of Excellence launched to address increase use of OTC drugs

Ferguson, the founding professional agency of CommonHealth, today announced the launch of the Ferguson OTC (over-the-counter) Center of Excellence, a new initiative designed to address the rapid increase of promotion and use of OTC drugs.

2 Sep 2009

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

The U.S. Food and Drug Administration (FDA) has approved Astepro (azelastine) nasal spray 0.15% for the treatment of the symptoms of seasonal and perennial allergic rhinitis.

2 Sep 2009

Corticosteroid and antiviral agent combination proves to be beneficial for treating Bell Palsy

Among patients with Bell Palsy, a facial paralysis with unknown cause, treatment with corticosteroids is associated with a reduced risk of an unsatisfactory recovery, and treatment with a combination of corticosteroids and antiviral agents may be associated with additional benefit, according to a systematic review and meta-analysis of previously published studies, reported in the September 2 issue of JAMA.

2 Sep 2009

ACTICOAT Flex 3 and ACTICOAT Flex 7 launched in Europe

Smith & Nephew's (NYSE: SNN) (LSE: SN) Advanced Wound Management division, announce the European launch of ACTICOAT™ Flex 3 and ACTICOAT™ Flex 7, to expand the ACTICOAT portfolio. The Flex range provides enhanced conformability to better address patient comfort and in utilizing the Silcryst™ nanocrystalline silver technology, ACTICOAT Flex products have been designed to support physicians dealing with soft tissue injuries at high risk of infection.

2 Sep 2009

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS).

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Positive results from second pivotal phase III trial for Lodotra

Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM).

2 Sep 2009

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

Mylan's subsidiary launches levalbuterol inhalation solution used for treating bronchospasm

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.

2 Sep 2009

Pharmaceutical News

Bextra qui tam lawsuit leads to Pfizer's whopping $2.3 billion settlement

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Hong Kong's healthcare workers to refuse H1N1 vaccine, says study

BioMS Medical update on dirucotide development

FDA approves Meda's ASTEPRO Nasal Spray

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

Cavit Sciences and McCoy form an agreement to finalize their merger

Combination of LIVALO and itraconazole drugs shows no adverse reactions

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Ferguson OTC Center of Excellence launched to address increase use of OTC drugs

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

Corticosteroid and antiviral agent combination proves to be beneficial for treating Bell Palsy

ACTICOAT Flex 3 and ACTICOAT Flex 7 launched in Europe

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Positive results from second pivotal phase III trial for Lodotra

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

Actelion launches new 20 mcg/mL Ventavis formulation

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Mylan's subsidiary launches levalbuterol inhalation solution used for treating bronchospasm

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News